Svendsen Samuel Levi, Rousing Amalie Quist, Carlsen Rasmus Kirkeskov, Khatir Dinah, Jensen Danny, Hansen Nikita Misella, Salomo Louise, Birn Henrik, Buus Niels Henrik, Leipziger Jens, Sorensen Mads Vaarby, Berg Peder
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.
J Am Soc Nephrol. 2024 Nov 1;35(11):1533-1545. doi: 10.1681/ASN.0000000000000447. Epub 2024 Jul 17.
This study developed a urine acid/base score to assess tubular acid excretion capacity and identify early acid retention in CKD. The results show that early signs of acid retention (a low acid/base score) are associated with a higher risk for CKD progression. Future research should address if a low urine acid/base score can be improved and if this translates into clinically meaningful effects.
Acidosis is associated with exacerbated loss of kidney function in CKD. Currently, acid/base status is assessed by plasma measures, although organ-damaging covert acidosis, subclinical acidosis, may be present before reflected in plasma. Low urine NH excretion associates with poor kidney outcomes in CKD and is proposed as a marker for subclinical acidosis. However, low NH excretion could result from either a low capacity or a low demand for acid excretion. We hypothesized that a urine acid/base score reflecting both the demand and capacity for acid excretion would better predict CKD progression.
Twenty-four–hour urine collections were included from three clinical studies of patients with CKD stage 3 and 4: a development cohort (=82), a variation cohort (=58), and a validation cohort (=73). A urine acid/base score was derived and calculated from urinary pH and [NH]. Subclinical acidosis was defined as an acid/base score below the lower limit of the 95% prediction interval of healthy controls. The main outcomes were change in measured GFR after 18 months and CKD progression (defined as ≥50% decline in eGFR, initiation of long-term dialysis, or kidney transplantation) during up to 10 years of follow-up.
Subclinical acidosis was prevalent in all cohorts (=54/82, 48/73, and 40/58, respectively, approximately 67%). Subclinical acidosis was associated with an 18% (95% confidence interval [CI], 2 to 32) larger decrease of measured GFR after 18 months. During a median follow-up of 6 years, subclinical acidosis was associated with a higher risk of CKD progression. Adjusted hazard ratios were 9.88 (95% CI, 1.27 to 76.7) in the development cohort and 11.1 (95% CI, 2.88 to 42.5) in the validation cohort. The acid/base score had a higher predictive value for CKD progression than NH excretion alone.
Subclinical acidosis, defined by a new urine acid/base score, was associated with a higher risk of CKD progression in patients with CKD stage 3 and 4.
本研究开发了一种尿酸碱评分系统,以评估肾小管酸排泄能力并识别慢性肾脏病(CKD)早期的酸潴留情况。结果显示,酸潴留的早期迹象(低酸碱评分)与CKD进展风险较高相关。未来的研究应探讨低尿酸碱评分是否可以改善,以及这是否能转化为具有临床意义的效果。
酸中毒与CKD患者肾功能的加速丧失有关。目前,酸碱状态通过血浆指标进行评估,尽管在血浆中出现反映之前,可能已经存在损害器官的隐匿性酸中毒,即亚临床酸中毒。CKD患者尿铵排泄量低与肾脏预后不良相关,并被提议作为亚临床酸中毒的标志物。然而,低铵排泄可能是由于酸排泄能力低或需求低所致。我们假设,反映酸排泄需求和能力的尿酸碱评分能更好地预测CKD进展。
纳入了三项针对3期和4期CKD患者的临床研究中的24小时尿液收集样本:一个开发队列(n = 82)、一个变异队列(n = 58)和一个验证队列(n = 73)。根据尿pH值和[NH]得出并计算尿酸碱评分。亚临床酸中毒定义为酸碱评分低于健康对照者95%预测区间的下限。主要结局为18个月后测得的肾小球滤过率(GFR)变化以及长达10年随访期间的CKD进展(定义为估算肾小球滤过率[eGFR]下降≥50%、开始长期透析或肾移植)。
所有队列中亚临床酸中毒均很常见(分别为54/82、48/73和40/58,约67%)。亚临床酸中毒与18个月后测得的GFR下降幅度大18%(95%置信区间[CI],2%至32%)相关。在中位随访6年期间,亚临床酸中毒与CKD进展风险较高相关。在开发队列中,校正后的风险比为9.88(95%CI,1.27至76.7),在验证队列中为11.1(95%CI,2.88至42.5)。酸碱评分对CKD进展的预测价值高于单独的铵排泄量。
由新的尿酸碱评分定义的亚临床酸中毒与3期和4期CKD患者的CKD进展风险较高相关。